Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 11/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989104 | 0.87 | AKR1C3 (0.53) | KMT2ANPC1RAB9AHSP90AA1HSP90AB1 | |
| SCHEMBL25984931 | 0.86 | PARP1 (0.58) | HSP90AA1HSP90AB1CA12CA1CA9 | |
| SCHEMBL2981524 | 0.86 | HSP90AA1 (0.43) | KMT2AMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL21280074 | 0.84 | HSP90AA1 (0.42) | KMT2AMEN1NPC1RAB9AHSP90AA1 | |
| SCHEMBL30785086 | 0.84 | STS (0.50) | KMT2AMEN1ALDH1A1HSP90AA1HSP90AB1 | |
| SCHEMBL4346540 | 0.84 | L3MBTL1 (0.50) | KMT2AMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL2982620 | 0.84 | ESR1 (0.42) | KMT2AMEN1NPC1ALDH1A1HSP90AA1 | |
| SCHEMBL16554270 | 0.84 | CA12 (0.40) | KMT2AMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL555801 | 0.83 | GSK3B (0.48) | NPC1RAB9AHSP90AA1HSP90AB1CA12 | |
| SCHEMBL2676116 | 0.83 | HSP90AA1 (0.41) | KMT2ANPC1RAB9AHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| CN-110804072-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-110790789-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2022-09-20 | — | — | US | disclosed |
| EP-3572410-B1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2022-07-20 | — | — | EP | disclosed |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-11-03 | — | — | US | disclosed |
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2020-07-30 | — | — | US | disclosed |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-7989449-B2 | 4,5-dihydro-oxazol-2-yl amine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2264017-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | KMT2A 4335/4885MEN1 3871/4885MAOB 453/4885 |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | BACE2, BACE1, PSEN2 | KMT2A 1424/4885MEN1 346/4885MAOB 680/4885 |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | KMT2A 4295/4885MEN1 3644/4885MAOB 407/4885 |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | KMT2A 3197/4885MEN1 2661/4885MAOB 1137/4885 |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | KMT2A 4335/4885MEN1 3871/4885MAOB 453/4885 |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | KMT2A 1516/4885MEN1 2389/4885MAOB 2542/4885 |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | KMT2A 4335/4885MEN1 3871/4885MAOB 453/4885 |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | KMT2A 4335/4885MEN1 3871/4885MAOB 453/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | KMT2A 4335/4885MEN1 3871/4885MAOB 453/4885 |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | KMT2A 4335/4885MEN1 3871/4885MAOB 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.